Table 2.
Distributions of primary and recurrent urothelial carcinoma by site, stage, and grade.
| Site/stage/grade | Primary n = 103∗ Number (%) |
Primary n = 48# Number (%) |
Recurrent n = 29 Number (%) |
|---|---|---|---|
| Site | |||
| Bladder | 68 (66.0%) | 22 (45.8%) | 29 (100.0%) |
| Ureter | 15 (14.6%) | 11 (22.9%) | 0 (0.0%) |
| Renal pelvis | 12 (11.6%) | 9 (18.8%) | 0 (0.0%) |
| Renal collecting duct | 1 (1.0%) | 1 (2.1%) | 0 (0.0%) |
| Bladder and renal pelvis | 2 (1.9%) | 1 (2.1%) | 0 (0.0%) |
| Bladder, ureter, and renal pelvis | 1 (1.0%) | 0 (0.0%) | 0 (0.0%) |
| Ureter and renal pelvis | 4 (3.9%) | 4 (8.3%) | 0 (0.0%) |
| Stage | |||
| Ta | 34 (33.0%) | 8 (16.7%) | 7 (24.1%) |
| T1 | 31 (30.1%) | 15 (31.2%) | 12 (41.4%) |
| T2 | 28 (27.2%) | 20 (41.7%) | 6 (20.7%) |
| T3+T4 | 10 (9.7%) | 5 (10.4%) | 4 (13.8%) |
| Grade | |||
| PNLMP | 9 (8.7%) | 0 (0.0%) | 0 (0.0%) |
| Low | 29 (28.2%) | 11 (22.9%) | 5 (17.2%) |
| High | 65 (63.1%) | 37 (77.1%) | 24 (82.8%) |
Note: ∗patients performed the NMP22 BladderChek tests; #patients performed the NMP22 BladderChek tests and urine cytology tests; PNLMP: papillary neoplasm of low malignant potential.